What giredestrant is and why the adjuvant setting matters

Giredestrant (also known as GDC-9545) is an oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, designed to treat hormone receptor positive (HR+), HER2-negative breast cancer. Unlike fulvestrant — the injectable SERD that has been the standard of care for decades — giredestrant is administered orally, a formulation advantage that carries meaningful implications for patient adherence and real-world uptake in both the metastatic and, critically, the early adjuvant settings.

The adjuvant setting — treating patients after surgery to prevent recurrence — represents a substantially larger addressable population than the metastatic setting. According to data from WHO, HR+ breast cancer is the most common breast cancer subtype globally, accounting for the majority of new diagnoses each year. Shifting an effective SERD into the early disease setting, where patients are treated with curative intent, would represent a significant commercial and clinical milestone for whichever compound succeeds first.

Roche’s evERA trial (evaluating giredestrant in early-stage HR+ breast cancer) is a Phase III adjuvant study designed to test whether giredestrant can reduce recurrence risk in this population. Patent filings from Genentech describe methods of treating HR+ breast cancer with giredestrant, including in patients who have received prior CDK4/6 inhibitor therapy — a patient population that is growing rapidly as CDK4/6 inhibitors become established in the adjuvant setting itself, per guidance from bodies such as ESMO.

Genentech’s giredestrant patent portfolio: scope and combination strategies

Genentech’s patent strategy for giredestrant extends well beyond the core compound claim, building a multi-layered portfolio that covers combination therapies, patient selection biomarkers, crystal forms, and specific disease indications. Patent analysis across US and WO jurisdictions reveals at least four distinct combination axes that Genentech has sought to protect: CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and anti-HER2 agents.

The earliest filings, dating to 2019, cover methods of treating breast cancer with SERDs including GDC-9545 in patients with estrogen receptor mutations — a prescient claim that anticipated the clinical importance of ESR1 mutations as a resistance mechanism. By 2022–2023, the portfolio had expanded to cover giredestrant in combination with palbociclib (a CDK4/6 inhibitor), inavolisib (a PI3K inhibitor), and everolimus (an mTOR inhibitor), each filed as separate patent families in both WO and US jurisdictions. A 2023 filing specifically covers combination with anti-HER2 antibodies or antibody drug conjugates (ADCs), reflecting the growing interest in treating HER2-low and HER2-positive tumours with endocrine-based regimens.

A notable 2023 Roche filing (WO-2023186007-A1) covers crystal forms A and B of a SERD compound, extending IP protection into the formulation space — a common late-stage portfolio strategy to protect commercial product forms. Taken together, the Genentech/Roche giredestrant portfolio reflects a deliberate effort to build IP fences not just around the molecule itself, but around every clinically relevant combination context and patient population in which it might be used.

“Genentech’s giredestrant patent portfolio spans compound claims, crystal forms, combination therapies with CDK4/6 inhibitors, PI3K inhibitors, everolimus, and anti-HER2 ADCs — a multi-layered IP strategy designed to protect every clinically relevant use of the molecule.”

The oral SERD competitive landscape: four challengers mapped

Giredestrant is not developing the oral SERD adjuvant space in isolation. At least four other oral SERDs have filed substantive patent portfolios covering HR+ breast cancer treatment methods, and several are in late-stage clinical trials that could reach readout ahead of, or concurrent with, the evERA data.

Imlunestrant (Eli Lilly)

Eli Lilly’s imlunestrant has generated the most concentrated burst of recent patent activity among giredestrant’s competitors. Three separate patent families (WO-2024086815-A1, WO-2024086835-A1, WO-2024086804-A1), all published in April 2024, cover methods of treating ER+ breast cancer with imlunestrant, including in combination with abemaciclib — Lilly’s own CDK4/6 inhibitor. The strategic logic is clear: Lilly is positioning imlunestrant as a natural successor or complement to abemaciclib in the HR+ setting, leveraging its existing commercial infrastructure and physician relationships built around Verzenio. According to FDA guidance on combination endocrine therapies, the CDK4/6 plus endocrine backbone is now well-established, making the SERD-plus-CDK4/6 combination a logical next step.

Camizestrant (AstraZeneca, AZD9833)

AstraZeneca’s camizestrant (AZD9833) has patent coverage for treating ER+ HER2-negative metastatic breast cancer, with claims covering both monotherapy and combination with CDK4/6 inhibitors. Two US patent publications (US-2022380413-A1 and US-2024165099-A1) specifically describe patient populations with no prior, one, or more lines of prior endocrine therapy — positioning camizestrant across the treatment continuum. AstraZeneca’s SERENA Phase III programme is evaluating camizestrant in the advanced setting, with potential implications for future adjuvant studies.

Elacestrant (Radius Pharmaceuticals / Menarini)

Elacestrant holds a distinct first-mover advantage: it is the first oral SERD to receive regulatory approval, having been cleared by the FDA for ESR1-mutated advanced or metastatic HR+/HER2-negative breast cancer following the EMERALD trial. Patent filings from Radius Pharmaceuticals cover methods of treating cancer with elacestrant based on ESR1 mutation status (WO-2023102444-A1), as well as combination with abemaciclib and PI3K pathway inhibitors including alpelisib, inavolisib, and everolimus (WO-2024163879-A1). Elacestrant’s approved status in the metastatic ESR1-mutated setting gives it a commercial beachhead, though its adjuvant programme is less advanced than giredestrant’s.

Rintodestrant (Olimmune LLC)

Rintodestrant, covered by Olimmune LLC patents (WO-2024112949-A1), is described for use in HR+/HER2-negative breast cancer in combination with CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and anti-HER2 ADCs — a combination profile that closely mirrors giredestrant’s own patent claims. Rintodestrant is at an earlier stage of clinical development than the other three competitors, but its patent activity signals continued investment in the oral SERD space.

ESR1 mutations as a biomarker battleground across the SERD class

ESR1 mutations — activating mutations in the gene encoding estrogen receptor alpha — have emerged as the defining biomarker in HR+ breast cancer endocrine resistance, and they feature prominently in the patent claims of multiple oral SERD programmes. These mutations arise primarily in the metastatic setting following aromatase inhibitor therapy, conferring ligand-independent ER activation and resistance to standard endocrine agents.

Genentech’s 2019 filing (WO-2019168999-A1) was among the earliest to claim methods of treating breast cancer patients with estrogen receptor mutations using giredestrant, establishing IP priority in this biomarker-selected population. Radius Pharmaceuticals has similarly filed patent claims specifically directed to treating cancer with elacestrant based on ESR1 mutation status (WO-2023102444-A1) — a claim that directly reflects elacestrant’s FDA-approved indication, which is restricted to ESR1-mutated tumours based on the EMERALD trial data.

The biomarker question becomes more complex in the early adjuvant setting, where ESR1 mutations are rare at diagnosis — they emerge predominantly under selective pressure from metastatic endocrine therapy. This means the evERA trial and its competitors in the early setting must demonstrate benefit in an essentially ESR1 wild-type population, relying on the broader mechanism of complete ER degradation rather than ESR1 mutation-specific activity. This distinction has important implications for trial design, patient selection, and the eventual labelling of any approved adjuvant SERD.

Patent filing trends and what they signal about the next phase

The trajectory of oral SERD patent filing activity from 2019 to 2024 reveals a class that has moved from early compound protection to a sophisticated, multi-dimensional IP landscape. Three trends are particularly instructive for understanding where the competitive dynamics are heading.

Trend 1 — Combination therapy claims are proliferating. Every major oral SERD programme has now filed combination claims covering CDK4/6 inhibitors, and most have extended to PI3K inhibitors and mTOR inhibitors. Genentech’s giredestrant portfolio covers combinations with palbociclib (CDK4/6), inavolisib (PI3K), and everolimus (mTOR). Eli Lilly’s imlunestrant claims cover combination with abemaciclib. Radius’s elacestrant claims cover combination with abemaciclib, alpelisib, inavolisib, and everolimus. This convergence means that the combination therapy space will be heavily contested, with freedom-to-operate analyses becoming increasingly important for any company seeking to develop a SERD-backbone combination regimen.

Trend 2 — Crystal form and formulation patents are emerging. Roche’s 2023 filing (WO-2023186007-A1) covering crystal forms A and B of a SERD compound, and a separate 2022 filing from Zhejiang Beta Pharma (WO-2022258068-A1) covering crystal forms of an oral SERD with molecular formula C29H26F3N3O4, signal that the field is maturing into the formulation protection phase. These filings typically accompany the transition from clinical to commercial-stage development and are a reliable leading indicator of regulatory submission timelines.

Trend 3 — Expanding indications beyond breast cancer. Genentech’s patent filings explicitly claim methods of treating lung cancer and endometrial cancer with giredestrant (WO-2021202866-A1), while other SERD patents reference endometrial and ovarian cancer. The Roche crystal form patent (WO-2023186007-A1) also mentions endometrial cancer. This suggests that the oral SERD class may ultimately have a broader oncology franchise than the current breast cancer focus implies — a consideration relevant to long-term portfolio valuation and competitive positioning, as tracked by organisations such as IQVIA in their oncology pipeline analyses.

For IP professionals and R&D strategists monitoring this space, the patent landscape as of early 2025 suggests that the window for uncontested freedom to operate in the oral SERD adjuvant space is narrowing rapidly. The combination of dense compound-level IP from Genentech, accelerating filing activity from Eli Lilly, and elacestrant’s first-approval precedent means that any new entrant — or any existing player seeking to expand its label — will need to navigate an increasingly complex patent thicket. PatSnap’s innovation intelligence platform, including PatSnap Eureka, provides the tools to map citation networks, prosecution histories, and claim scope across all five programmes simultaneously.